EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Prophylactic Administration of Mesenchymal Stromal Cells Does Not Prevent Arrested Lung Development in Extremely Premature-Born Non-Human Primates

Marius A Möbius iD, Steven R Seidner iD, Donald C McCurnin, Leonhard Menschner iD, Isabel Fürböter-Behnert, Julia Schönfeld iD, Jenny Marzahn, Daniel Freund iD, Nadine Münch, Sandra Hering, Shamimunisa B Mustafa, Diana G Anzueto und 5 weitere

Stem Cells Translational Medicine · 2023

DOI: 10.1093/stcltm/szac088 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Stem Cells Translational Medicine, 2023. Verfasst von Marius A Möbius und 16 weiteren Autor:innen. Beteiligte Einrichtung: Neonatology and Pediatric Critical Care Medicine, Department of Pediatrics, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dr…. Hauptthemen laut MEDLINE: Bronchopulmonary Dysplasia, Mesenchymal Stem Cells. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIH HHS, CIHR, Canadian Institutes of Health Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Premature birth is a leading cause of childhood morbidity and mortality and often followed by an arrest of postnatal lung development called bronchopulmonary dysplasia. Therapies using exogenous mesenchymal stromal cells (MSC) have proven highly efficacious in term-born rodent models of this disease, but effects of MSC in actual premature-born lungs are largely unknown. Here, we investigated thirteen non-human primates (baboons; Papio spp.) that were born at the limit of viability and given a single, intravenous dose of ten million human umbilical cord tissue-derived MSC per kilogram or placebo immediately after birth. Following two weeks of human-equivalent neonatal intensive care including mechanical ventilation, lung function testing and echocardiographic studies, lung tissues were analyzed using unbiased stereology. We noted that therapy with MSC was feasible, safe and without signs of engraftment when administered as controlled infusion over 15 minutes, but linked to adverse events when given faster. Administration of cells was associated with improved cardiovascular stability, but neither benefited lung structure, nor lung function after two weeks of extrauterine life. We concluded that a single, intravenous administration of MSC had no short- to mid-term lung-protective effects in extremely premature-born baboons, sharply contrasting data from term-born rodent models of arrested postnatal lung development and urging for investigations on the mechanisms of cell-based therapies for diseases of prematurity in actual premature organisms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bronchopulmonary DysplasiaMesenchymal Stem CellsInfant, NewbornAnimalsHumansLungInfant, PrematurePrimates

Stichwörter der Autor:innen

adverse eventsbronchopulmonary dysplasiacell therapyextreme premature birthlung developmentunbiased stereology

Autor:innen und Institutionen

  • Neonatology and Pediatric Critical Care Medicine, Department of Pediatrics, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Saxony, Germany.
  • Saxonian Center for Feto/ Neonatal Health, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Saxony, Germany.
  • Good Manufacturing Practice, Center for Regenerative Therapies, Technische Universität Dresden, Dresden, Saxony, Germany.
  • Neonatology, Department of Pediatrics, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
  • Forensic Genetics, Institute for Legal Medicine, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Saxony, Germany.
  • Pathology Services, Laboratory Animal Resources, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.

ORCID-Profile: Marius A Möbius, Steven R Seidner, Leonhard Menschner, Julia Schönfeld, Daniel Freund, Mario Rüdiger, Bernard Thébaud

Förderung

  • NIH HHS
  • CIHR
  • Canadian Institutes of Health Research Foundation
  • Ontario Institute of Regenerative Medicine
  • Canadian Stem Cell Network
  • Children’s Hospital of Eastern Ontario Foundation
  • Gesellschaft für Neonatologie und Pädiatrische Intensivmedizin
  • Technische Universität Dresden

Zitieren

APA

Möbius, M. A., Seidner, S. R., McCurnin, D. C., Menschner, L., Fürböter-Behnert, I., Schönfeld, J., Marzahn, J., Freund, D., Münch, N., Hering, S., Mustafa, S. B., Anzueto, D. G., Winter, L. A., Blanco, C. L., Hanes, M. A., Rüdiger, M., & Thébaud, B. (2023). Prophylactic Administration of Mesenchymal Stromal Cells Does Not Prevent Arrested Lung Development in Extremely Premature-Born Non-Human Primates. Stem Cells Translational Medicine. https://doi.org/10.1093/stcltm/szac088

Vancouver

Möbius MA, Seidner SR, McCurnin DC, Menschner L, Fürböter-Behnert I, Schönfeld J, et al. Prophylactic Administration of Mesenchymal Stromal Cells Does Not Prevent Arrested Lung Development in Extremely Premature-Born Non-Human Primates. Stem Cells Translational Medicine. 2023. doi:10.1093/stcltm/szac088

BibTeX
@article{Mbius2023,
  author = {Möbius, Marius A and Seidner, Steven R and McCurnin, Donald C and Menschner, Leonhard and Fürböter-Behnert, Isabel and Schönfeld, Julia and Marzahn, Jenny and Freund, Daniel and Münch, Nadine and Hering, Sandra and Mustafa, Shamimunisa B and Anzueto, Diana G and Winter, Lauryn A and Blanco, Cynthia L and Hanes, Martha A and Rüdiger, Mario and Thébaud, Bernard},
  title = {Prophylactic Administration of Mesenchymal Stromal Cells Does Not Prevent Arrested Lung Development in Extremely Premature-Born Non-Human Primates},
  journal = {Stem Cells Translational Medicine},
  year = {2023},
  doi = {10.1093/stcltm/szac088}
}
Kostenlos starten →